An investigational therapeutic vaccine showed clinical effectiveness in patients with human papillomavirus (HPV)16-positive ...
A therapeutic vaccine targeting human papillomavirus type 16 (HPV16) induced regression in high-grade precancerous cervical lesions, according to the results from a phase II clinical trial.
TWO women lose their lives to cervical cancer every day in the UK. Like all types of the disease, the earlier it’s caught, the better. Around 95 per cent of those diagnosed at stage 1 will ...
With 90 to 95 per cent of cervical cancer cases caused by the human papillomavirus (HPV), vaccination offers a nearly 99 per cent protection rate against the disease. Prince Court Medical Centre ...